share_log
Breakings ·  Sep 27 23:06
Bristol Myers Squibb Presents New Data From Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment